Investor Presentaiton slide image

Investor Presentaiton

Investor presentation Full year 2018 Slide 98 NovoEight® volumes continue to grow despite increasing penetration of long-acting FVIII products Novo Eight® roll-out continues and the number of patients has steadily increased Estimated number of patients¹ 3,000 Number of launch countries Number of patients 2,500 2,000 1,500 1,000 35 28 25 500 16 8 2014 2015 2016 2017 2018 Novo Eight® has potential to increase volume share in selected segments and markets Competitive positioning for Novo Eight® • Temperature stability at high room temperature and best-in- class portability . Uptake driven by Novo Nordisk's strong customer focus and company recognition within the haemophilia community • Continued volume growth especially in less mature markets with tender opportunities, despite increasing penetration of long-acting FVIII products 1 Novo Nordisk estimated accumulated patient number. Patient number in 2018 as of November 2018 FVIII: Coagulation factor VIII novo nordisk
View entire presentation